Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients

Antiviral Therapy

Volumn 14, Issue 5, 2009, Pages 649-654

  Pollicino, Teresa ^a   Isgrò, Graziella ^a   Di Stefano, Rosa ^b   Ferraro, Donatella ^b   Maimone, Sergio ^a   Brancatelli, Santa ^a   Squadrito, Giovanni ^a   Di Marco, Vito ^b   Craxi, Antonio ^b   Raimondo, Giovanni ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE;

ADULT; AMINO ACID SUBSTITUTION; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE ANALYSIS; STOP CODON; VIRAL GENETICS; VIRUS ISOLATION; VIRUS LOAD;

ADULT; AGED; DRUG RESISTANCE, VIRAL; FEMALE; GENETIC VARIATION; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME;

EID: 69849093597     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Bartholomeusz A, Locarnini S. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006; 26:162-170.
2. Bartholomeusz A, Locarnini S. Hepatitis B virus mutations associated with antiviral therapy. J Med Virol 2006; 78:S52-S55.
3. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 2006; 44:593-606.
4. Zoulim F, Buti M, Lok AS. Antiviral-resistant hepatitis B virus: can we prevent this monster from growing? J Viral Hepat 2007; 14 Suppl 1:29-36.
5. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46:254-265.
6. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45:1056-1075.
7. Ghany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007; 132:1574-1585.
8. Pawlotsky JM, Dusheiko G, Hatzakis A, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008; 134:405-415.
9. Delaney WE, Locarnini S, Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antivir Chem Chemother 2001; 12:1-35.
10. Bartholomeusz A, Tehan BG, Chalmers DK. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir Ther 2004; 9:149-160.
11. Bock CT, Tillmann HL, Torresi J, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122:264-273.
12. Sheldon J, Rodès B, Zoulim F, Bartholomeusz A, Soriano V. Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat 2006; 13:427-434.
13. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 2002; 25:97-106.
14. Sloan RD, Ijaz S, Moore PL, Harrison TJ, Teo CG, Tedder RS. Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant. Antivir Ther 2008; 13:439-447.
15. Torresi J, Earnest-Silveira L, Deliyannis G, et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002; 293:305-313.
16. Pollicino T, Raffa G, Costantino L, et al. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology 2007; 45:277-285.
17. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitiviry of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties an weight matrix choice. Nucleic Acids Res 1994; 22:4673-4680.
18. Schildgen O, Sirma H, Funk A, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006; 354:1807-1812.
19. Borroto-Esoda K, Miller MD, Arterburn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol 2007; 47:492-498.
20. Curtis M, Zhu Y, Borrota-Esoda K. Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir. J Infect Dis 2007; 196:1483-1486.
21. Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistance mutations. J Hepatol 2008; 48:391-398.
22. Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006; 44:422-431.
23. Pawlotsky J-M. The concept of hepatitis B virus mutant escape. J Clin Virol 2005; 34 Suppl 1:S125-S129.
24. Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 1997; 4 Suppl 1:11-20.
25. Torresi J, Earnest-Silveira I, Civitico G, et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002; 299:88-99.
26. Ando K, Moriyama T, Guidotti LG, et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med 1993; 178:1541-1554.
27. Bock CT, Tillmann HL, Maschek HJ, Manns MP, Trautwein C. A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly. Gastroenterology 1997; 113:1976-1982.
28. Galibert F, Mandart E, Fitoussi F, Tiollais P, Charnay P. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. Coli. Nature 1979; 281:646-650.